Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports. | Available online http arthritis-research.eom content 10 3 R53 Research article Discontinuation rates in clinical trials in musculoskeletal pain meta-analysis from etoricoxib clinical trial reports R Andrew Moore Sheena Derry and Henry J McQuay Open Access Pain Research and Nuffield Department of Anaesthetics University of Oxford Oxford Radcliffe Hospital The Churchill Oxford OX3 7LJ UK Corresponding author R Andrew Moore andrew.moore@pru.ox.ac.uk Received 15 Jan 2008 Revisions requested 25 Feb 2008 Revisions received 19 Mar 2008 Accepted 8 May 2008 Published 8 May 2008 Arthritis Research Therapy 2008 10 R53 doi 10.1186 ar2422 This article is online at http arthritis-research.com content 10 3 R53 2008 Moore et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Introduction Patient adherence to therapy in clinical practice is often low and the difference between efficacy measured in clinical trials and effectiveness in clinical practice is probably a function of discontinuation of therapy because of lack of efficacy or because of unmanageable or intolerable adverse events. Discontinuation is frequently measured in clinical trials but is not usually described in detail in published reports often because of limitations in the size of publications. By contrast company clinical trial reports include much more detail. Methods We examined company clinical trial reports of trials involving etoricoxib in four musculoskeletal conditions osteoarthritis rheumatoid arthritis chronic low back pain and ankylosing spondylitis. Information was available from 18 randomized trials 10 143 patients lasting 4 to 12 weeks one 4 weeks three 6 weeks one 8 weeks and seven 12 weeks and from three trials with a mean duration of about 80 weeks